Clinique Saint-Pierre Ottignies (CSPO)
- Address
- lock Available on a paid plan
Oncology and Hematology
At Clinique Saint-Pierre Ottignies, a large share of research focuses on cancer and blood disorders, with studies in breast cancer, prostate cancer, lung cancer, multiple myeloma, lymphoma, and leukemia. These trials are mainly designed to test new treatment combinations, improve disease control, and compare emerging therapies with current standards.
- Breast cancer, including hormone receptor-positive, HER2-negative, HER2-low, and triple-negative disease
- Prostate cancer, including metastatic castration-resistant and castration-sensitive forms
- Hematologic cancers such as multiple myeloma, chronic lymphocytic leukemia, and non-Hodgkin lymphoma
- Lung cancer and other solid tumors, with an emphasis on treatment effectiveness
The site’s oncology portfolio reflects a strong interest in both targeted and immune-based approaches, alongside studies aimed at improving outcomes for patients with advanced or difficult-to-treat disease.
Respiratory and Critical Care Research
Research in respiratory medicine and intensive care is especially prominent at this health care site, where trials examine pneumonia, acute respiratory distress syndrome, viral lung infection, COVID-19, and sepsis. The main goal is to evaluate new supportive treatments and better strategies for severely ill hospitalized patients.
- Severe community-acquired pneumonia and hospital-acquired pneumonia
- Acute respiratory distress syndrome and other serious lung infections
- Viral pneumonia, including COVID-19-related disease
- Sepsis and sepsis-associated organ injury
These studies often aim to reduce complications, improve recovery, and lower the risk of death in critically ill patients treated in intensive care settings.
Cardiovascular and Neurological Care
Another important research area involves cardiovascular disease and neurology, with trials in cardiac arrest, stroke, and post-anoxic brain injury. The research is centered on evaluating therapies that may protect the brain, support recovery, and improve outcomes after life-threatening events.
- Acute ischemic stroke and related recovery-focused care
- Cardiac arrest and comatose survivors
- Post-cardiac arrest syndrome and brain injury prevention
- Seizure control after resuscitation-related brain injury
At CSPO, this work highlights a commitment to improving urgent care for patients with sudden neurological or cardiac emergencies.
Infectious Diseases and Antimicrobial Innovation
Trials in bacterial infections and mycoses explore better ways to treat serious infections in hospitalized patients, including community-acquired pneumonia, bloodstream infection, and intra-abdominal infection. The purpose is to assess new anti-infective strategies, refine treatment duration, and improve clinical recovery.
- Severe bacterial pneumonia and other serious respiratory infections
- Bloodstream and intra-abdominal infections in critically ill patients
- Hospital infection management and antimicrobial stewardship
- Infection-related complications such as sepsis and organ dysfunction
These studies support the search for safer, more effective infection care in high-risk hospital settings.
Reproductive, Urogenital, and Women's Health
Research also spans female urogenital diseases and pregnancy-related complications, with additional attention to human papillomavirus and women’s health in oncology. The trials in this area are aimed at improving prevention, clearance of infection, and treatment decisions for women with complex conditions.
- Genital HPV infection and prevention of persistent infection
- Breast cancer in premenopausal and postmenopausal women
- Pregnancy-related and female urogenital health concerns
- Personalized treatment approaches in hormone-sensitive disease
This work combines preventive research with treatment-focused studies that may help refine care for women across different stages of disease.
General and Unspecified Clinical Research
Some studies at the site do not fit neatly into a single therapeutic category, reflecting a broader clinical research portfolio. These trials often address complex hospital-based problems and are designed to test new approaches that may improve overall patient outcomes.
- Mixed inpatient conditions requiring intensive monitoring
- Supportive care strategies in severe illness
- Broad evaluations of treatment benefit and safety
- Research aimed at improving recovery in diverse patient groups
The range of topics shows that Clinique Saint-Pierre Ottignies contributes to both highly specialized and cross-cutting clinical research in Europe.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 7 therapeutic areas and 15 of 123 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 118 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 18 by active trials.
- 1AstraZeneca AB5active
lock +17 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB6trials
lock +5 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 307 other sites in Belgium
Therapeutic Area Benchmark — Belgium
Select a therapeutic area to compare against other sites in Belgium.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Belgium
Market Share
Country: Belgium
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Clinique Saint-Pierre Ottignies (CSPO)
lock Showing 1 of 46 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Double-blind, Placebo-controlled Study of JNJ-78278343, a T-cell-redirecting Agent Targeting Human Kallikrein 2 Versus Placebo for Metastatic Castration-resistant Prostate Cancer | Janssen Cilag International | Phase III | Recruiting | Nov 2025 | — |
IMP list
lock Showing 1 of 123 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Paclitaxel | 6 | Unknown | 2019-01-02 | 2026-04-23 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
